FDA advisers endorse natalizumab for Crohn's disease.
Traynor
Kate
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069442:Natalizumab; D014481:United States; D014486:United States Food and Drug Administration